ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
May 16 2023 - 8:00AM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically proven and
practical products that improve the health and productivity of
dairy and beef cattle, today announced that its 2023 Annual
Meeting of Stockholders will be conducted virtually.
The Annual Meeting will be held by remote communication in the
form of a telephone conference call and a live audio webcast,
rather than as an in-person event.
The Annual Meeting will take place Thursday, June 15, 2023, at
9:00 AM ET. Stockholders of record of the Company’s common stock at
the close of business on April 14, 2023, are invited to participate
in the Annual Meeting by dialing (844) 855-9502 toll free or (412)
317-5499 for international access or by accessing the live audio
webcast at https://app.webinar.net/YpXM2OMeGOA. Participation via
the live audio webcast will be in listen-only mode. Participation
in the informal Q&A session, which will take place after the
formal business of the meeting is concluded, will be limited to the
telephone conference call connection.
A meeting replay will be available for seven days after the
meeting by dialing (877) 344-7529 toll free or (412) 317-0088 for
international access, using replay access code: 7542765 until June
22, 2023.
Stockholders, regardless of their plans to attend the
virtual-only meeting, are encouraged to vote and submit their
proxies in advance of the Annual Meeting using one of the methods
described in the proxy materials. Stockholders may continue to use
the voting instruction form or proxy card provided, and no
additional action is required to be taken by stockholders who have
already submitted their proxy. Stockholders that would like to vote
at the Annual Meeting (instead of by proxy) should contact the
Company’s Voting Inspector in advance of the meeting at (207)
878-2770 Ext. 0 or via email at: mail@immucell.com to arrange to
vote during the meeting.
Investors are encouraged to review the Company’s Form 10-Q for
the three-month period ended March 31, 2023 that was filed with the
SEC on Thursday, May 11, 2023 and its updated Corporate
Presentation slide deck that provides an overview of the Company’s
business and is available under the “Investors” tab of the
Company’s website at www.immucell.com, or by request to the
Company. For more information about the Annual Meeting, including
the matters to be voted on during the Annual Meeting, please see
the Company’s Notice of Annual Meeting of Stockholders and its
Proxy Statement, which are available, along with the 2022 Annual
Report on Form 10-K, at www.immucell.com.
About ImmuCell:ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create scientifically
proven and practical products that improve the health and
productivity of dairy and beef cattle. ImmuCell manufactures and
markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain®, a novel treatment for subclinical
mastitis in dairy cows without a milk discard requirement that
provides an alternative to traditional antibiotics. Press releases
and other information about the Company are available at:
http://www.immucell.com.
Contacts: |
Michael F. Brigham, President and CEOImmuCell Corporation (207)
878-2770Joe Diaz, Robert Blum and Joe DorameLytham Partners,
LLC(602) 889-9700iccc@lythampartners.com |
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2024 to May 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From May 2023 to May 2024